BR0010349C1 - Derivados de ácido propanóico que inibem a ligação de integrinas aos seus receptores - Google Patents

Derivados de ácido propanóico que inibem a ligação de integrinas aos seus receptores

Info

Publication number
BR0010349C1
BR0010349C1 BR0010349-7A BR0010349A BR0010349C1 BR 0010349 C1 BR0010349 C1 BR 0010349C1 BR 0010349 A BR0010349 A BR 0010349A BR 0010349 C1 BR0010349 C1 BR 0010349C1
Authority
BR
Brazil
Prior art keywords
receptors
acid derivatives
propanoic acid
integrin binding
inhibit
Prior art date
Application number
BR0010349-7A
Other languages
English (en)
Other versions
BR0010349B1 (pt
BR0010349A (pt
Inventor
Ronald J Biediger
George W Holland
Jamal M Kassir
Wen Li
Robert V Market
Ian L Scott
Chengde Wu
Original Assignee
Texas Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26830910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0010349(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Texas Biotechnology Corp filed Critical Texas Biotechnology Corp
Publication of BR0010349A publication Critical patent/BR0010349A/pt
Publication of BR0010349C1 publication Critical patent/BR0010349C1/pt
Publication of BR0010349B1 publication Critical patent/BR0010349B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"DERIVADOS DE áCIDO PROPANóICO QUE INIBEM A LIGAçãO DE INTEGRINAS AOS SEUS RECEPTORES". Um método para a inibição da ligação de integrina <244>~ 4~<225>~ 1~ aos seus receptores, por exemplo, VCAM-1 (molécula de adesão de célula vascular-1) e fibronectina; compostos que inibem esta ligação; composições farmaceuticamente ativas compreendendo tais compostos; e o uso de tais compostos ou como acima ou em formulações para o controle ou prevenção de estados de doença em que <244>~ 4~<225>~ 1~ está envolvida.
BRPI0010349-7A 1999-05-07 2000-05-05 derivados de ácido propanóico que inibem a ligação de integrinas aos seus receptores. BR0010349B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13296799P 1999-05-07 1999-05-07
US17044199P 1999-12-10 1999-12-10
PCT/US2000/012464 WO2000068188A1 (en) 1999-05-07 2000-05-05 Propanoic acid derivatives that inhibit the binding of integrins to their receptors

Publications (3)

Publication Number Publication Date
BR0010349A BR0010349A (pt) 2003-07-08
BR0010349C1 true BR0010349C1 (pt) 2003-11-04
BR0010349B1 BR0010349B1 (pt) 2011-10-04

Family

ID=26830910

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0010349-7A BR0010349B1 (pt) 1999-05-07 2000-05-05 derivados de ácido propanóico que inibem a ligação de integrinas aos seus receptores.

Country Status (23)

Country Link
EP (1) EP1189881B2 (pt)
JP (2) JP4841729B2 (pt)
KR (1) KR100767199B1 (pt)
CN (1) CN100360499C (pt)
AT (1) ATE277923T1 (pt)
AU (1) AU4826900A (pt)
BR (1) BR0010349B1 (pt)
CA (1) CA2373180C (pt)
CZ (1) CZ304225B6 (pt)
DE (1) DE60014369T3 (pt)
ES (1) ES2228527T5 (pt)
HK (1) HK1044533A1 (pt)
HU (1) HU229155B1 (pt)
IL (2) IL146312A0 (pt)
MX (1) MXPA01011341A (pt)
NO (1) NO329899B1 (pt)
NZ (1) NZ515249A (pt)
RO (1) RO121640B1 (pt)
RU (1) RU2255933C9 (pt)
SI (1) SI20876B (pt)
SK (1) SK288186B6 (pt)
TR (1) TR200103427T2 (pt)
WO (1) WO2000068188A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
PE20020420A1 (es) 2000-10-02 2002-06-27 Novartis Ag Derivados de diazacicloalcanodiona como antagonistas del antigeno asociado a la funcion del linfocito-1 (lfa-1)
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
PL374598A1 (en) 2002-06-28 2005-10-31 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
AU2003265398A1 (en) 2002-08-09 2004-02-25 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
US7612091B2 (en) 2002-12-20 2009-11-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
US7501538B2 (en) 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
US7544699B2 (en) 2003-08-08 2009-06-09 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
EP1828144A2 (en) 2004-11-12 2007-09-05 OSI Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
ES2600460T3 (es) 2005-05-10 2017-02-09 Intermune, Inc. Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés
KR20080031379A (ko) 2005-07-11 2008-04-08 와이어쓰 글루타메이트 아그레카나제 저해제
KR20080058436A (ko) 2005-10-13 2008-06-25 와이어쓰 글루탐산 유도체의 제조 방법
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
EP3773573B1 (en) 2018-04-12 2026-03-18 Morphic Therapeutic, Inc. Antagonists of human integrin (alpha4)(beta7)
TWI775182B (zh) 2019-10-16 2022-08-21 美商莫菲克醫療股份有限公司 抑制人類整合素αβ
CN118354999A (zh) * 2022-01-11 2024-07-16 深圳信立泰药业股份有限公司 一种哒嗪-1(6h)-6-氧代类化合物及其制备方法与应用
WO2024235299A1 (zh) * 2023-05-17 2024-11-21 西藏海思科制药有限公司 一种羧基衍生物及其在医药上的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
GR851819B (pt) * 1984-08-17 1985-11-26 Wyeth John & Brother Ltd
WO1992019595A1 (en) * 1991-05-07 1992-11-12 Merck & Co., Inc. Fibrinogen receptor antagonists
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
EP0761680A3 (en) * 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
NZ333904A (en) * 1996-07-25 2000-06-23 Biogen Inc VLA-4 and IIb/IIIa cell adhesion inhibitors
JP2002511052A (ja) * 1996-08-29 2002-04-09 メルク エンド カンパニー インコーポレーテッド インテグリンアンタゴニスト
AU738341B2 (en) * 1996-10-11 2001-09-13 Abbott Gmbh & Co. Kg Asparate ester inhibitors of interleukin-1beta converting enzyme
DE19647380A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
AR016751A1 (es) * 1996-11-22 2001-08-01 Athena Neurosciences Inc Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
NZ500620A (en) * 1997-05-02 2000-10-27 Akzo Nobel Nv Synthetic peptides which inhibit serine proteases, specifically thrombin, factor VIIa tissue factor and factor Xa
DE19741235A1 (de) * 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6331640B1 (en) * 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
WO2000061631A1 (en) * 1999-04-12 2000-10-19 Astrazeneca Ab Modified pentapeptide antagonists of the atrial natriuretic peptide clearance receptor

Also Published As

Publication number Publication date
RU2255933C9 (ru) 2005-11-20
SI20876B (sl) 2009-08-31
NO20015419D0 (no) 2001-11-06
NO329899B1 (no) 2011-01-24
NO20015419L (no) 2001-12-20
CA2373180A1 (en) 2000-11-16
PL354957A1 (en) 2004-03-22
DE60014369T2 (de) 2005-11-24
IL146312A (en) 2010-12-30
DE60014369D1 (de) 2004-11-04
DE60014369T3 (de) 2013-06-27
CZ20013983A3 (cs) 2002-04-17
JP2012006932A (ja) 2012-01-12
JP4841729B2 (ja) 2011-12-21
KR100767199B1 (ko) 2007-10-17
TR200103427T2 (tr) 2002-10-21
RO121640B1 (ro) 2008-01-30
EP1189881B2 (en) 2013-01-23
EP1189881B1 (en) 2004-09-29
RU2255933C2 (ru) 2005-07-10
BR0010349B1 (pt) 2011-10-04
WO2000068188A1 (en) 2000-11-16
JP2002544187A (ja) 2002-12-24
HUP0202184A3 (en) 2003-03-28
ES2228527T3 (es) 2005-04-16
HUP0202184A2 (hu) 2002-12-28
MXPA01011341A (es) 2002-06-21
CZ304225B6 (cs) 2014-01-15
KR20020009608A (ko) 2002-02-01
CA2373180C (en) 2009-12-15
JP5468578B2 (ja) 2014-04-09
CN100360499C (zh) 2008-01-09
IL146312A0 (en) 2002-07-25
EP1189881A1 (en) 2002-03-27
SI20876A (sl) 2002-10-31
SK16092001A3 (sk) 2002-04-04
ES2228527T5 (es) 2013-05-23
EP1189881A4 (en) 2002-11-27
NZ515249A (en) 2004-07-30
HK1044533A1 (zh) 2002-10-25
SK288186B6 (sk) 2014-05-06
CN1370143A (zh) 2002-09-18
AU4826900A (en) 2000-11-21
ATE277923T1 (de) 2004-10-15
WO2000068188A9 (en) 2002-08-29
BR0010349A (pt) 2003-07-08
HU229155B1 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
BR0010349C1 (pt) Derivados de ácido propanóico que inibem a ligação de integrinas aos seus receptores
BR9909626A (pt) Compostos que inibem a ligação de integrina a seus receptores
DK1176956T3 (da) Carboxylsyrederivater, som inhiberer bindingen af integriner til deres receptorer
NO20015394L (no) Karboksylsyrederivater som hemmer bindingen av integriner til deres reseptorer
ATE420876T1 (de) Propansäurederivate die die bindung von integrinen an ihre rezeptoren hemmen
BR0316104A (pt) Produtos de combinação com derivados ácido carboxìlico que inibem a ligação de integrins aos seus receptores e outros compostos terapêuticos
BR0106840A (pt) Derivados de ácido carboxìlico que inibem a ligação de integrinas aos seus receptores
BR0010293A (pt) Derivados de ácido carboxìlico que inibem a ligação de integrinas para seus receptores

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: C07C 229/00, C07D 213/06, A61K 31/435, A61P 29/00

Ipc: C07C 315/00 (2009.01), C07C 229/00 (2009.01), C07C

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/10/2011, OBSERVADAS AS CONDICOES LEGAIS.

B25D Requested change of name of applicant approved

Owner name: ENCYSIVE PHARMACEUTICALS, INC. (US)

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: NOME ALTERADO DE: TEXAS BIOTECHNOLOGY CORPORATION

Owner name: ENCYSIVE PHARMACEUTICALS, INC. (US)

Free format text: NOME ALTERADO DE: TEXAS BIOTECHNOLOGY CORPORATION

B25G Requested change of headquarter approved

Owner name: ENCYSIVE PHARMACEUTICALS, INC. (US)

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110121314/RJ DE 25/11/2011.

Owner name: ENCYSIVE PHARMACEUTICALS, INC. (US)

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110121314/RJ DE 25/11/2011.

B24B Patent annual fee: requirement for complementing annual fee

Free format text: REFERENTE A 13A ANUIDADE, DE ACORDO COM TABELA VIGENTE, GUIA DE RECOLHIMENTO 92120357377-3.

B24D Patent annual fee: restoration after fee payment
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: ADDITIONAL INVENTOR'S CERTIFICATE:

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)